Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 12, 2022
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
[ Wed, Oct 12th 2022
] - WOPRAI
Matthew Taylor Initiated (TNDM) at Strong Buy and Held Target at $75 on, Oct 12th, 2022
Matthew Taylor of Jefferies, Initiated "Tandem Diabetes Care, Inc." (TNDM) at Strong Buy and Held Target at $75 on, Oct 12th, 2022.
Matthew has made no other calls on TNDM in the last 4 months.
There are 4 other peers that have a rating on TNDM. Out of the 4 peers that are also analyzing TNDM, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Matthew
- Larry Biegelsen of "Wells Fargo" Downgraded from Buy to Sell and Decreased Target to $49 on, Tuesday, August 9th, 2022
- Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $82 on, Thursday, August 4th, 2022
- Matt O'Brien of "Piper Sandler" Maintained at Buy with Decreased Target to $80 on, Thursday, August 4th, 2022
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $90 on, Thursday, August 4th, 2022
